Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

176.07 +0.97 (+0.55%)
Streaming Delayed Price Updated: 10:43 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data 
Via Stocktwits
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio. 
Via Stocktwits
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
Via Stocktwits
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
Via Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
Via Stocktwits
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
Via Stocktwits
News headline image
Why Is ALVO Stock Rising Pre-Market Today? ↗
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints. 
Via Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
Via Stocktwits
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗
Via Stocktwits
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Why Did SER Stock Surge Over 70% In Pre-Market Today? ↗
The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease. 
Via Stocktwits
News headline image
This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF ↗
The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation. 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
News headline image
Why This Fund Cashed Out of a $3.6 Million Biotech ETF Bet ↗
After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings. 
Via Stocktwits
Topics Artificial Intelligence Stocks
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
Via MarketBeat
News headline image
Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now ↗
Clean Energy’s Second Wind: What iShares Global Clean Energy ETF Tells Us Now 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals ↗
Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗
Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
Via Benzinga
Topics ETFs
News headline image
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.